Please ensure Javascript is enabled for purposes of website accessibility

Get It Together, Johnson & Johnson

By Brian Orelli, PhD – Updated Apr 6, 2017 at 10:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another day, another recall.

Just when you thought it was safe to come back to the drugstore after Johnson & Johnson's (NYSE: JNJ) children's Tylenol returned to the shelves, the company has issued another product recall.

This one doesn't seem quite as bad as many of the others. There are no musty odors. The drug inside doesn't seem to have anything wrong with it.

Instead, Johnson & Johnson is recalling 9.3 million bottles of three Tylenol Cold Multi-Symptom products because the labels on the front of the bottles don't note that the contents contain alcohol.

We're talking about less than 1% of the contents being alcohol. That's under two proof, for those wondering if this could actually get you drunk.

In fact, there's nothing really the matter, except that Johnson & Johnson realized it should make sure customers know that there's a teensy weensy bit of alcohol in the bottle. From an investors' standpoint, there's two ways to think about this; neither is all that appealing.

One possibility is that the notice is really necessary, and Johnson & Johnson could get in big trouble with the Food and Drug Administration if it isn't on the label. In that case, one has to wonder how the labels got this far through quality control without anyone noticing.

Or Johnson & Johnson could just be overreacting to its quality-control issues. Sure, it would be nice for customers to have the information on the front of the bottle, but it's on the outside package and the back of the bottle. Given its quality-control issues, Johnson & Johnson might be a little overly cautious at this point.

Either way, it seems that the recall just adds fuel to the fire, which helps companies such as Perrigo (Nasdaq: PRGO), which sells over-the-counter generic versions of some of Johnson & Johnson's drugs. In addition, GlaxoSmithKline (NYSE: GSK), Abbott Labs (NYSE: ABT), Merck (NYSE: MRK), and Pfizer (NYSE: PFE) all have consumer health divisions that could benefit from Johnson & Johnson's tarnished reputation.

Johnson & Johnson is a good company, and I'm sure it'll be able to turn itself around eventually. But until the recalls end, investors should proceed with caution.

Alex Dumortier thinks irrational exuberance is back.

Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is a Motley Fool Income Investor recommendation. Pfizer is a Motley Fool Inside Value recommendation. The Fool owns shares of and has written covered calls on GlaxoSmithKline, which is a Motley Fool Global Gains pick. The Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.83 (-0.57%) $0.25
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$99.84 (-0.83%) $0.84
GSK Stock Quote
GSK
GSK
$28.82 (-1.84%) $0.54
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.18 (-0.69%) $0.60
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.70 (-0.61%) $-1.02
Perrigo Company plc Stock Quote
Perrigo Company plc
PRGO
$37.66 (-1.13%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.